Studies have suggested that activation of AMPK by metformin prevents the development of PAH in animal models and activation of AMPK prevents the development of PAH by targeting nuclear factor-kappa B (NF-κB) to suppress autophagy and vascular remodeling (47, 48). This evidence concerns the gene NFKB1 and pulmonary arterial hypertension.